Objective: To evaluate differences in soluble inflammatory markers between chronically HIV-infected men and women, with or without cognitive impairment, and in response to treatment.
Introduction
Immune activation is a critical component of HIV pathogenesis and a strong predictor of disease progression [1] . Sex-based differences in HIV-infected individuals have been described previously for viral set point [2, 3] , disease progression [4] , and cellular activation [5] . These studies revealed women have lower viral loads and higher CD4 þ T-cell counts than men; however, at the same level of viremia, women progressed more rapidly to AIDS (reviewed in [6] ). The immunological basis of these sex differences is not well understood, and sex-based comparisons of soluble marker levels have not been thoroughly investigated in chronic HIV infection or following initiation of combination antiretroviral therapy (cART).
In the earliest days following HIV acquisition, CD4
þ T cells are depleted from gut associated lymphoid tissue, compromising the integrity of the gut barrier. This event leads to translocation of microbial products, which in turn can drive systemic immune activation [7] . Markers of microbial translocation and enterocyte damage, such as intestinal fatty acid binding protein (I-FABP) and sCD14, are elevated in untreated HIV infection likely because of increased gut permeability and chronic activation of CD4 þ T cells [1] . In addition to infecting gut lymphoid tissue, viral RNA is found in other organs, as well as the central nervous system (CNS), as evidenced by cerebrospinal fluid (CSF) HIV RNA immediately following infection [8] [9] [10] . In chronic HIV-1 infection, up to 50% of individuals are noted to have cognitive impairment, termed HIV-Associated Neurological Disorder (HAND) [11] . There is growing evidence that persistent chronic immune activation may contribute to CNS complications [12] , as the inflammatory response is considered to be the main mediator of neuronal damage in HAND [13] . As infection progresses, HIV triggers an inflammatory response within the CNS, resulting in macrophage activation and increased expression of neopterin, a surrogate marker of neurocognitive impairment. Treatment-naive, HIV-infected patients with dementia express high levels of neopterin within plasma and CSF [14] . Furthermore, elevated cell-associated viral reservoir burden in monocyte-enriched peripheral blood cells is associated with cognitive impairment in treatment-naive patients and is directly associated with markers of immune activation within the CSF [15] .
The widespread use of cART to combat HIV has led to a considerable decrease in HIV-associated morbidity and mortality [16, 17] . In response to therapy, expression levels of inflammatory biomarkers decrease, plasma and CSF viral loads decline, and patients with HAND improve cognitively [18] [19] [20] . Although survival rates of HIV infected individuals have dramatically improved because of treatment, these individuals are at increased risk for a variety of conditions that lead to early mortality [19, 21] including heart disease, cancer, kidney disease, bone density loss, and cognitive impairment [19, 22] . A growing body of evidence implicates persistent inflammation and immune activation, despite cART, as a contributor to immunosenescence and these age-associated conditions [21, 23, 24] .
This study aimed to uncover differences in levels of inflammatory markers that may contribute to sex differences in HIV disease progression and response to cART. We measured an array of soluble factors in plasma and CSF of chronically HIV-infected men and women prior to and following treatment to identify variations in these markers that may contribute to differences in disease progression. We compared levels of these soluble factors in HIV-1-infected individuals to those in uninfected individuals within the same region. Most reported studies to date have analyzed HIV-1 subtype B or C infections, and this study is unique to the sex differences in CRF_01 AE infections in Thailand. These efforts propose sexspecific differences in biomarkers previously linked to cognitive impairment, chronic inflammation, and gut integrity that may contribute to immunological differences between sexes in relationship to disease progression and response to therapy.
Methods

Study design
Sixty treatment-naive Thais (25 men and 35 women) with chronic HIV infection were recruited to investigate markers of cognitive impairment among cART-naïve HIV-infected individuals who met Thai Ministry of Public Health criteria for initiating cART (CD4 þ cell count <350 cells/ml or symptomatic disease) as part of the SEARCH 011 study protocol (NCT00782808) [15] . All participants were chronically infected with HIV, cARTnaïve, and agreed to begin therapy upon enrollment. Participants were evaluated by a consensus panel of clinical neurology and neuropsychology tests to assign HAND diagnosis as cognitively normal, asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), or HIV-associated dementia (HAD). Participants then started first-line cART with lamivudine þ nevirapine þ either stavudine, zidovudine, or tenofovir. Participants intolerant to this regimen were changed based on clinical acumen, typically to efavirenz (EFV) for nevirapine complications. There was no difference in treatment regimens when stratified by sex.
Plasma and CSF samples were collected prior to, and at 48 and 96 weeks following cART initiation. Forty-two out of the 60 participants at enrollment and 14 participants at 48 weeks underwent lumbar puncture. Eighteen uninfected Thai men (N ¼ 9) and women (N ¼ 9) were enrolled as controls. All participants provided a signed consent, approved by the University of California, (San Francisco, CA), Walter Reed Army Institute of Research (Silver Spring, MD), and the Chulalongkorn University and Phramongkutklao Hospital (Bangkok, Thailand) Institutional Review Boards.
CD4
R T cells and plasma HIV-1 RNA HIV RNA and CD4 þ T-cell counts were measured using Cobas Amplicor (Roche Molecular Diagnostics, Pleasanton, California, USA), and flow cytometry, respectively, as described previously [15, 25] .
Soluble factor analysis
Matched pre-and posttreatment CSF and citrate-plasma specimens were analyzed for soluble activation markers. A custom multiplex ELISA array was used to quantify 13 analytes, including IFN-g, TNFa, TNF-RII, IL-1a, IL1b, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-15, and MCP-1, according to the manufacturer's instructions (Quansys Biosciences). Single-analyte ELISAs were performed to measure t-Tau and IP-10 (Life Technologies), neopterin (GenWay Biotech), IFNa, I-FABP, and sCD14 (R&D Systems) and analyzed using SoftMax Pro (Molecular Devices).
Statistical analyses
Multiple regression models were used to assess the association between soluble factor levels and sex adjusting for HIV-1 viral load, CD4 þ cell counts, and/or severity of neurocognitive disease as covariates using sex as an independent variable. There was no main interaction effect in these models; therefore, we performed a secondary outcome-hypothesis generating analysis by separating the sexes while controlling for viral load and CD4
þ absolute values. Analysis was also performed without controlling for viral load and CD4
þ absolute values, and the results were consistent with results controlling for these parameters (data not shown). Independent groups were compared using MannWhitney tests. Matched paired data from pre-cART and post-cART were analyzed by Wilcoxon signed rank test. Spearman's coefficient was used for correlation analyses. The threshold for statistical significance was set to P < 0.05 for all analyses. Data were graphed using PRISM software (version 6; Graphpad Software, La Jolla, California, USA).
Results
Study population characteristics
Among the 60 chronically HIV-infected, treatment-naïve Thais, there were no sex differences based on age or plasma or CSF viral load (Table 1 , Fig. 1 ) at the time of enrollment, although women trended towards lower plasma viral load (P ¼ 0.07), as previously reported [4, 6] . Differences in the time of acquisition were unknown; both men and women presented with chronic HIV infection and were immune compromised sufficient to initiate ART. There were no differences in CD4 þ T-cell counts (Table 1, Fig. 1c ), which may indicate that infection duration was similar between groups. After 48 weeks of cART, nearly all participants had undetectable viral RNA in the plasma and CSF ( Fig. 1a and b ) and increased CD4
þ T-cell counts (Fig. 1c) . When stratified by sex, no differences were detected in the HIV RNA levels or CD4 þ T-cell counts following treatment ( Fig. 1 ), similar to other reports [26] .
Sex differences in biomarkers related to cognition Participants exhibiting ANI, MND, or HAD were grouped and labeled as 'impaired cognition'. Although no difference in plasma viral load was observed by sex or impaired status in cART-naive participants (Fig. 2a) , women with impaired cognition exhibited higher CSF viral load than men with impaired cognition (Fig. 2b ). There were also slightly more women (49%) diagnosed with cognitive impairment compared with men (44%), although these values were not statistically significant.
Neopterin, a key marker of cellular immune activation linked to HAND and produced by activated monocytes/ macrophages, was measured in both plasma and CSF. Similar to previous studies [27, 28] , we observed an increase in neopterin levels in both plasma and CSF in individuals with impaired cognition (Fig. 2c ). Individuals diagnosed with HAD, the most severe cognitive impairment, displayed the highest levels of neopterin compared with those with normal cognition (data not shown), as described previously [27] .
Multiple regression models were used to assess the association between soluble factor levels and sex adjusting for HIV-1 viral load, CD4 þ cell counts, and/or severity of neurocognitive disease. In these models that included sex as a covariate, no main interaction effect was observed; therefore, we performed a secondary analysis by separating the sexes while controlling for viral load and CD4
þ absolute values. In these secondary analyses, when these findings were stratified by sex, only women with cognitive impairment exhibited significantly elevated neopterin levels in both plasma and CSF ( Fig. 2d and e) compared with women with normal cognition. In contrast, men with cognitive impairment did not exhibit elevated levels of neopterin compared with men with normal cognition in the plasma (P ¼ 0.68) or CSF (P ¼ 0.59) (Fig. 2d and e) . Plasma neopterin levels remained elevated in impaired women even after 48 weeks of cART (Fig. 2f ), yet no significant difference was detected in men between impaired and unimpaired groups (P ¼ 0.59). A reduced participation of volunteers for CSF collection did not allow sufficient data for statistical analysis after 48 weeks of cART for this compartment. The severity of impairment improved with treatment, as neither women nor men were diagnosed with HAD after 48 weeks of cART, and instead were diagnosed with less severe forms of cognitive impairment, MND or ANI (data not shown).
As observed previously, TNF-a and TNF-RII were elevated in impaired versus unimpaired individuals when combining sexes into one group prior to the initiation of treatment (Fig. 4, [29] ). Although no sex differences were statistically significant in multivariable models, evaluation of TNF-a and TNF-RII stratified by sex revealed that TNF-RII displayed the same trends as neopterin, wherein women with cognitive impairment exhibited significantly elevated TNF-RII levels compared with women with normal cognition in both the plasma and CSF even after 48 weeks of treatment ( Fig. 2h and i) . Men with impaired cognitive ability did not display elevated levels ( Fig. 2h and i) . There was no significant difference observed between cognitive impairment and sex in levels of TNFa. Tau, another biomarker investigated for association with HAND [30] , was also measured in the CSF. We found no difference in t-Tau levels in HIVinfected women or men with impaired compared with normal cognition (Fig. 2g) . Sex differences prior to and after initiation of treatment Further analyses were performed to determine the impact of cART on various soluble biomarker levels unrelated to cognition, and to determine if sex differences related to treatment were present. Sex differences in response to treatment were pronounced in expression levels of MCP-1, IL-8, IL-10, I-FABP, and sCD14 (Fig. 3) . Interestingly, within this population, uninfected and cART-naive infected men expressed higher levels of MCP-1 compared with uninfected and cART-naive infected women in both the plasma (P < 0.01) and CSF (P < 0.01) (Fig. 3a, data not shown) . Treatment decreased plasma MCP-1 levels in men, but did not affect plasma MCP-1 levels in women (Fig. 3a) . Levels were similar in both sexes after 48 weeks of treatment; however, these plasma levels remained significantly elevated in both sexes compared with uninfected controls (Fig. 3a) .
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Similarly, expression levels of IL-8, IFNa, and IL-10 were elevated in cART-naive chronically HIV infected men and women compared with uninfected controls (Fig. 3b-d) . Although IL-8 levels decreased after 48 weeks of treatment in women, these levels did not decrease in treated men (Fig. 3b) . IFNa and IL-10 plasma levels in both men and women decreased significantly following 48 weeks of treatment ( Fig. 3c and d) . IFNa remained elevated in both men and women compared with uninfected controls after 48 weeks of treatment (Fig. 3c) . Likewise, IL-10 remained significantly elevated in HIV-infected women (Fig. 3d) , whereas in infected men, IL-10 decreased to levels found in uninfected controls (Fig. 3d) . IFNa levels were not measured in the CSF; there was no significant difference in the levels of IL-8 or IL-10 in the CSF when stratified by sex or cognition (data not shown). No differences were detected in the IL-8, IL-10, or IFNa levels between men and women prior to the initiation of ART (Fig. 3b-d) .
Analysis of plasma I-FABP and sCD14 was performed to assess the differences in gut integrity between sexes. In contrast to the other biomarkers, I-FABP, a marker of enterocyte turnover, increased in both sexes following 48 weeks of cART (Fig. 3e) , although these increased levels only reached significance in women compared with men (Fig. 3e) . Levels of sCD14, a marker associated with early mortality in HIV infection [1] , remained unchanged in women throughout the course of treatment, whereas men significantly decreased sCD14 expression with treatment (Fig. 3f) . In both sexes, sCD14 remained elevated compared with uninfected controls (Fig. 3f) . Taken together, these findings reveal variations in these biomarkers between sexes in response to treatment.
Inflammatory markers remain elevated after treatment in chronically HIV-infected individuals independent of sex Subsequent analysis of all infected individuals demonstrated there was a significant decrease in the expression levels of neopterin, IP-10, TNFa, and TNF-RII (Fig. 4) following 48 weeks of cART with no significant difference between men and women when stratified by sex (Fig. 4) . Neopterin levels were significantly reduced in the plasma and CSF after 48 weeks of treatment ( Fig. 4a  and b ), but remained elevated compared with uninfected controls. Although these levels in the plasma continued to be elevated, neopterin levels in the CSF reduced to the same level as uninfected controls following 48 weeks of cART (Fig. 4b) , consistent with previously published literature [31] . IP-10, TNF-a, and TNF-RII levels decreased with treatment in both sexes, yet these levels remained elevated in the plasma compared with uninfected controls (Fig. 4c-h ). Both TNF-a and TNF-RII remained elevated in the CSF after 48 weeks of cART (Fig. 4f and h) , and IP-10 levels continued to be elevated in the CSF for women (Fig. 4d) . CSF IP-10 levels within HIV uninfected control men were increased compared with uninfected women (Fig. 4d) . In addition, levels of IL-6 significantly decreased to uninfected control levels following 48 weeks of cART with no significant difference between sexes (data not shown). Other biomarkers measured were not statistically elevated at enrollment (IL-1a, IL-1b, IL-4, IL-5, IL-12, IL-15, and IFN-g).
Discussion
Studies comparing the course of HIV infection between men and women have demonstrated considerable sex differences in disease progression [4, 32] and immune activation [5] . Although ART has dramatically reduced the risk of AIDS-associated opportunistic infections and mortality, chronic inflammation persists despite suppression of plasma HIV RNA leading to immunosenescence and age-related diseases [19, 21] . The causes of persistent systemic immune activation when therapy successfully controls viral burden are unclear, but likely result from multiple factors including residual HIV-1 replication within the mucosa or other viral reservoirs, prevalence of other co-infections [33] , damage to gut integrity and leakage of gut microbial products [7] , damage to the lymphoid tissues, and immunoregulatory cell loss [34] [35] [36] . Remarkably, women have an increased risk of early mortality even after treatment with ART compared with treated men [32] . Therefore, considerations need to be made in regards to the differences between these demographic populations that factor treating persistent chronic immune activation, in addition to HIV infection, to alleviate the onset of aged-related conditions.
Here we evaluated the differences in inflammatory markers between chronically HIV-infected men and women that may result in varied responses to ART and disease progression. We first demonstrate that women with impaired cognitive ability express elevated levels of neopterin and TNF-RII compared with women with normal cognitive ability; however, a significant difference was not observed in HIV-1 infected men. It has been documented previously that a greater number of HIV-1þ women develop cognitive deficits than men in Zambia, and the authors of that study suggested this may be because of sex-related social or healthcare disadvantages [37] . Within the current study, cognitive improvement following treatment initiation occurred at the same rate in both genders, although a larger percentage of women (23%) were still diagnosed with cognitive impairment after 48 weeks of treatment compared with men (15%); however, this result was not significant.
Sex-specific differences were detected in response to treatment in levels of MCP-1, IL-8, IL-10, I-FABP, and sCD14, whereas we did not observe a significant different in IFNa levels between men and women. Previous studies have demonstrated that plasmacytoid dendritic cells (pDCs) from women produced significantly higher levels of IFNa in response to HIV than pDCs from men, and these increased levels of IFNa secretion led to stronger activation of CD8 þ T cells in vitro [5] . The authors suggested that these increased levels of immune activation may contribute to faster HIV-1 disease progression in women. We did not observe increased systemic IFNa levels between chronically infected men and women in Thailand prior to or following treatment while controlling for viral load and CD4 þ T-cell count. These data may suggest that IFNa levels quantified from pDCs may be more reflective of local responses resulting in long-term chronic inflammation compared with systemic levels.
In stark contrast to the other soluble biomarkers, plasma I-FABP, a marker of enterocyte growth and proliferation, was elevated in women and men within the same HIVR soluble factor sex differences Krebs et al. demographic on cART, yet only reached significance in women. Furthermore, we found that levels of sCD14, another marker of microbial translocation, only decreased in men following 48 weeks of cART. Previous studies have shown that sCD14 is an independent predictor of disease progression and mortality in HIV infection [1] . We did not detect significant differences between men and women in levels of sCD14 prior to ART, but the continued elevation of sCD14 levels within women may be predictive of increased mortality after treatment as was found with previous studies [23] .
Other studies have determined the effect of cART on microbial translocation markers, such as I-FABP and sCD14, and similarly found I-FABP levels increased in individuals taking EFV [38] . In our study, there was no correlation between I-FABP levels and treatment with EFV, and there was no bias of EFV usage in women over men. Overall, there was no difference in the treatment modalities between sexes that would account for these outcomes. Because these individuals were chronically infected, gut integrity is likely impaired at this stage, and increased I-FABP and sCD14 levels in women after treatment may be reflective of local HIV replication and resulting destruction. Evidence of greater gut damage in the female participants may also result from pharmacological side effects not as evident in male participants. The cause of increased I-FABP levels after treatment remains to be determined.
We also provide evidence that after 1-2 years of cART, neopterin, IP-10, TNFa, TNF-RII, and IFNa significantly decreased in both men and women, but remained elevated compared with uninfected controls. MCP-1, IL-8, IL-10, I-FABP, and sCD14 also remain elevated compared with uninfected controls, but levels of these factors in each sex differ in responses to treatment. Remarkably, even in the absence of detectable viral load within the plasma and CSF, these inflammatory signals still persist. Levels of several other soluble factors found to be associated with acute infection [39] [40] [41] such as IL-1a, IL-1b, IL-4, IL-5, IL-6, IL-12, IL-15, or IFN-g were rarely detectable in these chronically infected individuals prior to cART initiation. This data suggests that not all pathways of immune activation continue to be amplified in chronic infection.
In conclusion, we demonstrate chronically HIV-infected individuals manifest elevated levels of inflammatory soluble factors even after 1-2 years of cART compared with uninfected controls. The levels of a subset of these soluble factors vary between men and women before and after treatment, and these sex-specific variations may underlie previously reported sex differences in the outcome of HIV disease progression. Strengths of this work include evaluating soluble factor levels in CRF_01 AE chronic infection, where there are few documented studies, available regionally appropriate control specimens, the longitudinal nature of the study, and a reasonable distribution of men and women from a selection criteria that did not include sex. However, the sample size was modest and in our robust multivariable statistical approach, we did not meet statistical significance for sex in these variables, despite prominent differences identified in exploratory approaches. In addition, because these individuals have not been followed longer than 2-3 years following ART initiation, we could not assess how the sustained elevation of these factors impact long-term disease progression and non-AIDS morbidity and mortality within this cohort. Our work could be strengthened by an evaluation of these factors in a larger sample of men and women and following these individuals long-term to determine biological relevance of these inflammatory soluble factors between sex.
Understanding sex differences between immune responses during HIV infection, especially differences in biomarkers linked to subclinical cognitive impairment and/or gut integrity, may inform complex decisions surrounding measures to reduce the long-term effects of chronic inflammation.
